Racial Disparities Persist in Curative Treatment for Early-Stage Non-Small Cell Lung Cancer

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 10, 2026.

via HealthDay

TUESDAY, March 10, 2026 -- Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March 2 in JAMA Network Open.

Olivia F. Lynch, M.D., from Yale University in New Haven, Connecticut, and colleagues used Surveillance, Epidemiology, and End Results Medicare-linked data (2005 to 2019) to examine trends in racial disparities in the receipt of curative treatment for early-stage NSCLC. The analysis included 28,287 non-Hispanic Black and non-Hispanic White patients (aged 66 to 85 years) who received a diagnosis of stage I or II NSCLC.

The researchers found that overall, 82.3 percent of patients received curative treatment. Adjusted probabilities of receiving curative treatment were significantly lower for Black patients compared with White patients in each time period (2005 to 2007: 73.9 percent of Black patients and 83.3 percent of White patients; 2011 to 2013: 76.3 and 85.2 percent; and 2017 to 2019: 78.4 and 86.8 percent). These disparities were associated primarily with surgical treatment across time (2005 to 2007: 52.3 percent of Black patients and 65.9 percent of White patients; 2011 to 2013: 48.3 and 61.0 percent; and 2015 to 2017: 43.7 and 53.1 percent). There was a sharp increase in stereotactic body radiotherapy use, with disparities seen only from 2011 to 2013 (39.6 of Black patients and 51.6 percent of White patients).

"If you’re developing cures for cancer, but it’s not getting into the hands of everybody who needs it, then you haven’t succeeded," Lynch said in a statement. "The next step has to ask why -- and what we’re going to do differently."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-11 08:43

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords